Evidence map›Paper›PMID 34481551›Full record

ArticleThe Lancet. Haematology2021

Child mortality from sickle cell disease in Nigeria: a model-estimated, population-level analysis of data from the 2018 Demographic and Health Survey.

Obiageli E Nnodu, Assaf P Oron, Alayo Sopekan, Godwin O Akaba, Frédéric B Piel, Dennis L Chao

Open access · hybridAbstract read
In one paragraph

Article in The Lancet. Haematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 3 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Genetics and Genomics in Sickle Cell Disease in Africa.American journal of hematology · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Genome editing strategies for targeted correction of β-globin mutation in sickle cell disease: From bench to bedside.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Obiageli E NnoduCentre of Excellence for Sickle Cell Disease Research and Training, University of Abuja, Abuja, Nigeria.
Assaf P OronInstitute for Disease Modeling, Bill & Melinda Gates Foundation, Seattle, WA, USA.
Alayo SopekanSickle Cell Disease Desk, Noncommunicable Diseases Control Programme, Department of Public Health, Federal Ministry of Health, Abuja, Nigeria.
Godwin O AkabaDepartment of Obstetrics and Gynaecology, College of Health Sciences, University of Abuja, Abuja, Nigeria.
Frédéric B PielDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Dennis L ChaoInstitute for Disease Modeling, Bill & Melinda Gates Foundation, Seattle, WA, USA. Electronic address: dennisc@idmod.org.
Bill & Melinda Gates Foundation · USUniversity of Abuja · NGFederal Ministry of Health · NGImperial College London · GB

Funding

The Sickle Pan-African Research Consortium (SPARCO)U24HL135881 · NHLBI · MUHIMBILI UNIVERSITY/ ALLIED HLTH SCIS · PI MAKANI, JULIE · 2017 to 2025
$5.3M
Sickle Pan African Research Consortium NigEria (SPARC-NEt)U01HL156942 · NHLBI · UNIVERSITY OF ABUJA · PI NNODU, OBIAGELI EUNICE · 2021 to 2025
$1.3M
Medical Research Council MR/L01341X/1Medical Research Council MR/S019669/1NHLBI NIH HHS U01 HL156942NHLBI NIH HHS U24 HL135881
6 · The paper itself

Abstract

backgroundChild mortality from sickle cell disease in sub-Saharan Africa is presumed to be high but is not well quantified. This uncertainty contributes to the neglect of sickle cell disease and delays the prioritisation of interventions. In this study, we estimated the mortality of children in Nigeria with sickle cell disease, and the proportion of national under-5 mortality attributable to sickle cell disease.

methodsWe did a model-estimated, population-level analysis of data from Nigeria's 2018 Demographic and Health Survey (DHS) to estimate the prevalence and geographical distribution of HbSS and HbSC genotypes assuming Hardy-Weinberg equilibrium near birth. Interviews for the survey were done between Aug 14 and Dec 29, 2018, and the embedded sickle cell disease survey was done in a randomly selected third of the overall survey's households. We developed an approach for estimating child mortality from sickle cell disease by combining information on tested children and their untested siblings. Tested children were aged 6-59 months at the time of the survey. Untested siblings born 0-14 years before the survey were also included in analyses. Testing as part of the DHS was done without regard to disease status. We analysed mortality differences using the inheritance-derived genotypic distribution of untested siblings older than the tested cohort, enabling us to estimate excess mortality from sickle cell disease for the older-sibling cohort (ie, those born between 2003 and 2013).

findingsWe analysed test results for 11 186 children aged 6-59 months from 7411 households in Nigeria. The estimated average birth prevalence of HbSS was 1·21% (95% CI 1·09-1·37) and was 0·24% (0·19-0·31) for HbSC. We obtained data for estimating child mortality from 10 195 tested children (who could be matched to the individual mother survey) and 17 205 of their untested siblings. 15 227 of the siblings were in the older-sibling cohort. The group of children with sickle cell disease born between 2003 and 2013 with at least one younger sibling in the survey had about 370 excess under-5 deaths per 1000 livebirths (95% CI 150-580; p=0·0008) than children with HbAA. The estimated national average under-5 mortality for children with sickle cell disease born between 2003 and 2013 was 490 per 1000 livebirths (95% CI 270-700), 4·0 times higher (95% CI 2·1-6·0) than children with HbAA. About 4·2% (95% CI 1·7-6·9) of national under-5 mortality was attributable to excess mortality from sickle cell disease.

interpretationThe burden of child mortality from sickle cell disease in Nigeria continues to be disproportionately higher than the burden of mortality of children without sickle cell disease. Most of these deaths could be prevented if adequate resources were allocated and available focused interventions were implemented. The methods developed in this study could be used to estimate the burden of sickle cell disease elsewhere in Africa and south Asia.

fundingSickle Pan African Research Consortium, and the Bill & Melinda Gates Foundation.

Indexed as

Anemia, Sickle CellChild MortalityHealth SurveysAdolescentChildChild, PreschoolFemaleHumansInfantInfant, NewbornMaleNigeriaPrevalence

Identifiers

PMID34481551
PMCPMC8460996
OpenAlexW3196878060

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.